ELECANACIN, A NOVEL NEW NAPHTHOQUINONE FROM THE BULB OF ELEUTHERINE AMERICANA

Hidemitsu HARA, ^a Naoki MARUYAMA, ^a Shinsuke YAMASHITA, ^a Yasuhisa HAYASHI, ^b Kuo-Hsiung Lee, ^c Kenneth F. BASTOW, ^c CHAIRUL, ^d Ryuji Marumoto, ^e and Yasuhiro IMAKURA*, ^a

Faculty of Sciences, Naruto University of Education,^a Takashima, Naruto-cho, Naruto-shi, Tokushima 770, Japan, Faculty of Sciences, Joetsu University of Education,^b Natural Products Laboratory, Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina,^c Chapel Hill, North Carolina 27599, U.S.A., Research & Development Centre for Biology, Indonesian Institute of Science,^d Jl. Juanda 18, Bogor, Indonesia, and Animal Health Research Laboratories, Agro Division, Takeda Chemical Industries LTD.,^e Jusohonmachi, Yodogawa-ku, Osaka 532, Japan

A novel new naphthoquinone called elecanacin (9) and a new naphthalene called isoeleutherol (10) were isolated from the bulb of *Eleutherine americana* MERR. *et* HEYNE (Iridaceae), together with two known naphthoquinones (2 and 3). The structures were determined by spectroscopic methods including the 2D-NMR techniques. Eleutherin (2) showed interesting inhibitory activity against human topoisomerase II, and isoeleutherin (3) and isoeleutherol (10) showed inhibitory activity against HIV.

KEY WORDS *Eleutherine americana*; Iridaceae; elecanacin; isoeleutherol; human topoisomerase II inhibitor; anti-HIV

Eleutherine americana MERR. et HEYNE (Iridaceae) is widely cultivated in Hainan Island, China, as a folk medicine to treat coronary disorders. Eleutherol (1), eleutherin (2), isoeleutherin (3), hongconin (4), and four anthraquinone derivatives ($5\sim8$) were isolated¹⁾ from the bulb of *E. americana*.

In our continuing search for bioactive naphtoquinone constituents from the plants of Iridaceae, we have isolated a new novel naphtoquinone called elecanacin (9) and a new naphthalene called isoeleutherol (10), together with 2 and 3, from the bulb of *E. americana*, which was collected on Java Island, Indonesia. This communication deals with the structural elucidation of elecanacin (9) and isoeleutherol (10), and the inhibitory activities

October 1997 1715

of 2, 3, 9, and 10 against human topoisomerase II (TOPO II) and human immunodeficiency virus (HIV).

The ethanol extract (14.6 g) of the bulb (dried weight, 5 kg) of *E. americana* was subjected to silica gel column chromatography followed by HPLC (Asahipak ODP 90) to yield eleutherin (2, 32 mg), isoeleutherin (3, 25 mg), elecanacin (9, 16 mg), and isoeleutherol (10, 12 mg).

Elecanacin (9), in the form of brown pillars, mp 196 \sim 197°C (Acetone), $[\alpha]_D$ + 20.7° (CHCl₃), was established as C₁₆H₁₆O₄ by HR-MS and elemental analysis. The ¹H- and ¹³C-NMR studies of 9 including ¹H- ¹H COSY and HMQC spectra suggested the structures [A, B, and C] shown in Fig. 1.




Fig. 1. Partial Structures Observed by ¹H and ¹³C-NMR, ¹H-¹H COSY, and HMQC Spectra (CDCl₃, δ) of **9**. (¹³C data in parentheses)

The connectivities of these partial structures were confirmed by the HMBC spectrum, leading to the partial structures [D and E] containing a novel four-membered ring and a tetrahydrofuran ring as shown by arrows in Fig. 2.




Fig. 2. HMBC Correlations [D and E] of 9

Fig. 3. NOE Correlations of B, C and D rings of **9**

The NOE correlations in the NOESY spectrum $[CDCl_3/C_6D_6(4:1)]$ of elecanacin provided evidence for the B/C *cis* and C/D *cis* ring fusions, as depicted by arrows in structure [F] in Fig. 3. The NOEs were observed when the interproton distances ranged from 2.430-2.582 Å.²⁾ Thus the stereostructure of elecanacin was established as **9**. To our knowledge, **9** is the first example of a 1,4-naphtoquinone derivative with a four-membered ring and a tetrahydrofuran ring in the molecule.

1716 Vol. 45, No. 10

The physical and spectral data³⁾ of Isoeleutherol (**10**) were similar to those of eleutherol (**1**),¹⁾ and its planar structure was determined from extensive analysis of the 2D NMR spectra (¹H-¹H COSY, HMQC, and HMBC). The specific rotation (CHCl₃) of **1** is +83°, and that of **10** is -60.5°. Consequently, the stereostructure of isoeleutherol is assumed to be the same as that of the enantiomer of eleutherol (**1**).

The inhibitory activities of compounds 2, 3, 9, and 10 against TOPO II and HIV were evaluated. For eleutherin (2) the IC $_{100}$ TOPO II, ^{4a)} EC $_{50}$ KB cells, ^{4b)} and EC $_{50}$ -7d cells ^{4b)} were 50, 14, and 5 μ g/ml, respectively, and compounds 3, 9, and 10 showed no activity. Eleutherin (2) appears to be interesting as a "noncleavable complex" type of TOPO II inhibitor with stereospecific and selective activity. Isoeleutherin (3) and isoeleutherol (10) demonstrated inhibitory activity against HIV replication in H9 lymphocytes with IC $_{50}$ and EC $_{50}$ values ^{4c)} of 8.55 and 100 μ g/ml, and 1.41 and 7.44 μ g/ml, respectively. Further studies on these and other constituents are now in progress and will be reported elsewhere.

REFERENCES AND NOTES

- 1) Chen Z., Huang H., Wang C., Li Y., Ding J., Sankawa U., Noguchi H., Iitaka Y., *Chem. Pharm. Bull.*, **34**, 2743-2746 (1986) and references cited therein.
- 2) The interproton distances (Å) were calculated using MM2 and MOPAC(PM3) parameters of CAChe (ver. 3.8).
- 3) Eleutherin (2): brown needles, mp 178 \sim 179 °C, [α]_D +220.7° (CHCl₃), C₁₆H₁₆O₄, IR(CHCl₃,cm⁻¹): 1685, 1600, 1500, ¹H-NMR(CDCl₃) δ : 1.36 (3H, d, J=6.5 Hz, 3-Me), 1.54 (3H, d, *J*=6.5 Hz, 1-Me), 2.20 (1H, dd, *J*=10.3, 18.1 Hz, 4-βH), 2.75 (1H, dd, $J=2.4,18.1 \text{ Hz}, 4-\alpha\text{H}$), 3.96 (1H, m, 3-H), 4.00 (3H, s, 9-OMe), 5.01 (1H, q, J=6.7 Hz, 1-H), 7.28 (1H, d, *J*=6.7 Hz, 8-H), 7.64 (1H t, *J*=6.7 Hz, 7-H), 7.74 (1H,d, *J*=6.7 Hz, 6-H). Isoeleutherin (3): brown needles, mp 174 \sim 175 °C, $[\alpha]_D$ +14.6° (CHCl₃), $C_{16}H_{16}O_4$, IR(CHCl₃, cm⁻¹): 1660, 1595, 1470, ¹H-NMR(CDCl₃) δ : 1.34 (3H, d, J=6.1Hz, 3-Me), 1.53 (3H, d, J=6.7 Hz, 1-Me), 2.23 (1H, dd, J=11.0,19.0 Hz, 4- β H), 2.69 (1H,dd, J=3.5, 19.0 Hz, $4-\alpha H$), 3.96 (1H, m, 3-H), 4.00 (3H, s, 9-OMe), 5.01 (1H, g, J=6.7Hz, 1-H), 7.27 (1H, d, *J*=6.7 Hz, 8-H), 7.64 (1H t, *J*=6.7Hz, 7-H), 7.74 (1H,d, J=6.7 Hz, 6-H). Isoeleutherol (10): brown needles, mp 202 \sim 203 °C, [α]_D -60.5° (CHCl₃), C₁₄H₁₂O₄, IR (CHCl₃, cm⁻¹): 3400, 1765; ¹H-NMR (CDCl₃) δ : 1.73 (3H, d, J=6.5 Hz, 1-Me),1.54 (3H, d, J=6.5 Hz, 1-Me), 4.11 (3H, s, 8-OMe), 5.70 (1H, q, J=6.5 Hz, 1-H), 6.93 (1H, d, J=7.7 Hz, 7-H), 7.39 (1H, t, J=7.7 Hz, 6-H), 7.54 (1H t, J=7.7 Hz, 5-H), 7.84(1H,s, 4-H), 9.63 (1H, s, 9-OH); 13 C-NMR (CDCl₃) δ : 19.18 (q, 11-C), 56.43 (q, 10-C), 76.64 (d, 1-C), 106.33 (d,7-C), 116.50 (d, 6-C),117.54 (s, 8a-C), 123.67 (d, 5-C), 125.92 (s, 3a-C), 126.61 (d, 4-C),127.94 (s, 9a-C), 137.24 (s, 4a-C), 149.20 (s, 9-C), 156.61 (s, 8-C), 170.55 (s, 3-C).
- 4) a) Tested versus calf thymus topoisomerase II-dependent DNA unknotting in vitro.
 - b) Tested for cell growth inhibition over continuous three-day exposure. The -7d cell line is resistant to VP-16 (a "cleavable-complex" type of topoisomerase II inhibitor) in part because it has reduced levels of enzyme.
 - c) TI $(IC_{50} / EC_{50}) \ge 5.0$ considered to be significant. Isoeleutherin (3): TI=6.07; isoeleutherol (10): TI=13.4